Tuesday, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) announced the topline results of its Phase 3 trial of Mino-Lok, an antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution.
Catheter failure was defined as the inability to administer study lock solution, catheter removal for any infection-related reason (including worsening ...